Mrinalini Dey

Clinical Research Fellow @KCLImmunoMicro•Rheumatology Registrar•@EMEUNET rep to EULAR-PARE•Editorial Board @RheumJnl•#Comorbidities #SocialDeterminantsOfHealth

[Mrinalini Dey @DrMiniDey]

Delighted to share our paper on #multimorbidity in #RA emphasising a need for:
-Operationalised definition of MM
-Clearer distinction between MM & #comorbidity in literature
-Greater understanding of MM to encourage holistic care
@RheumJnl @ElenaNikiUK

https://t.co/cpqR05uv9v

[Mrinalini Dey @DrMiniDey]

@MithuRheum @MaliniDey6 Yes we are 😄

[Mrinalini Dey @DrMiniDey]

First “Dey & Dey” article combining mine and @MaliniDey6’s interests in RMDs and cancer biology.
Hopefully the first of many more to come!
👯🏻‍♀️

[Armen Yuri Gasparyan @ArmenYuri]

PARP1 as a novel therapeutic and diagnostic tool in autoimmune rheumatic diseases: a systematic literature review
@DrMiniDey @dr_emrebilgin @ozlemkilic_md
https://t.co/dL5U6GsO5q

[Dr. Malini Dey @MaliniDey6]

Proud to share my first first-author publication published today in @Rheumatol_Int . It has been a rewarding project over the past 2 years. Thanks to my amazing sister & co-author @DrMiniDey for her guidance and support. 🤩 📝
https://t.co/xdFEzxL3bK

[Dr. John Cush @RheumNow]

RA-ILD: Screening risk and genetic susceptibility

Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.

https://t.co/VoY3HFjbjf

[The Journal of Rheumatology @jrheum]

Research Article

Perceived and Objective Physical Function in 2 United States Population-Based Cohorts of Adults With Systemic Lupus Erythematosus

📖 https://t.co/6rTGVwCleZ
@UCSFDOM @JYazdanyMD

#Aging #PhysicalFunction #Lupus

[Md Yuzaiful Md Yusof @Yuz6Yusof]

#EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃

https://t.co/fONe6g4ne1

[Dr. John Cush @RheumNow]

DAY 4 Recap: EULAR 2026 Highlights https://t.co/UhoyWaAmK8

[Mrinalini Dey @DrMiniDey]

#EULAR2026 Updated recommendations on the management of PMR &LVV.

A pleasure to have been part of this huge piece of work, covering 3 distinct conditions, and both diagnosis & management principles.

Watch this space for full guideline coming soon!

#EULAR2026
@RheumNow

[Mrinalini Dey @DrMiniDey]

An important reminder of the psychosocial determinants of outcomes in RA- it is not just about the pharmacological management.

https://t.co/FjFGAzDivX

@ElenaNikiUK @RheumNow #EULAR2026

[Mrinalini Dey @DrMiniDey]

Comorbidities don’t just impact prognosis, remission and treatment in RA- they impact mortality. Comorbidities cannot be treated in a “one size fits all” approach; they should be assessed and managed on an individual basis.

@ElenaNikiUK
@RheumNow #EULAR2026

[Mrinalini Dey @DrMiniDey]

Overview of the updated RA treatment guideline- early escalation to a biologic following commencement of methotrexate is key to achieving remission.

https://t.co/136ZQaiG2W

@ElenaNikiUK
@RheumNow
#EULAR2026

[Mrinalini Dey @DrMiniDey]

#EULAR2026

@ElenaNikiUK takes us through the paradigm shift in RA, with an in-depth overview of how far we’ve come in management.

@RheumNow

[Mrinalini Dey @DrMiniDey]

#OP0159 #EULAR2026
Multimodal study in D2T RA identified altered brain connectivity patterns linked to pain, psychological features & peripheral transcriptomics. Supports neuroimmune component in D2T RA & need for personalised approaches beyond inflammation control. @RheumNow

[Durga Prasanna Misra @DurgaPrasannaM1]

The #EULAR recommendations for the management of Polymyalgia Rheumatica and Large Vessel Vasculitis were presented today at #EULAR2026 at London by the task force lead Dr Chetan Mukhtyar. It was a privilege to represent India on this international task force! I hope these recommendations lead to the better management of patients with PMT, GCA and Takayasu Arteritis. Watch out for the publication of these recommendations in the future!

[Mrinalini Dey @DrMiniDey]

#OP0156 #EULAR2026 FT839, CART therapy targeting CD19 & CD38, showed potent depletion of pathogenic B cells, plasmablasts/plasma cells & activated T cells, w/o conditioning chemotherapy. Data suggest potentially more accessible CART approach across autoimmune diseases. @RheumNow

[Mrinalini Dey @DrMiniDey]

#OP0209 #EULAR2026 SPECIFI-RA

Balinatunfib, oral selective TNFR1 inhibitor designed to preserve TNFR2 signalling in RA. Phase 2b trial missed primary ACR20 endpoint, but 200mg QD arm showed signals for higher ACR50, ACR70 and DAS28 low disease activity & reduced IL-6. @RheumNow

[Mrinalini Dey @DrMiniDey]

#OP0208 #EULAR2026: phase 3 COURAGE-RA trial showed strong efficacy for selective JAK1 inhibitor zemprocitinib in D2T RA after bDMARD failure. Responses were rapid (from week 2), sustained through week 24 and achieved with a reassuring safety profile. @RheumNow

[Mrinalini Dey @DrMiniDey]

#OP0207 #EULAR2026: SUPERFIBRES trial suggests dietary fibre supplementation may enhance MTX response in RA. Inulin improved EULAR responses and Th17/Treg balance over 30 days, with strongest effects seen in MTX-treated patients. Fascinating microbiome-linked signal. @RheumNow

[Mrinalini Dey @DrMiniDey]

#OP0206 #EULAR2026: 🛴SCOOT trial compared oral split-dose vs SC MTX in early active RA. Non-inferiority of split-dose oral MTX was not shown, with several efficacy outcomes favouring SC MTX and more transaminitis seen with oral split dosing. @RheumNow

[Mrinalini Dey @DrMiniDey]

#OP0205 #EULAR2026: 🌞SUNSTAR head-to-head trial compared SC TOC vs Abatacept after failure of 1-2 b/tsDMARDs in RA. Primary CDAI endpoint was not met, but composite response and treatment persistence favoured tocilizumab. @RheumNow